Buscar en
Actas Urológicas Españolas (English Edition)
Toda la web
Inicio Actas Urológicas Españolas (English Edition) The potential diagnostic accuracy of circulating microRNAs for prostate cancer: ...
Journal Information
Vol. 46. Issue 3.
Pages 138-149 (April 2022)
Share
Share
Download PDF
More article options
ePub
Visits
0
Vol. 46. Issue 3.
Pages 138-149 (April 2022)
Review article
The potential diagnostic accuracy of circulating microRNAs for prostate cancer: A meta-analysis
La posible precisión diagnóstica de los microARN circulantes para el cáncer de próstata: un metaanálisis
Visits
...
W.T. Zhanga,b, G.X. Zhangb, R.Z. Zhaoc, S.S. Gaoa,b,
Corresponding author
631192403@qq.com

Corresponding author.
a Xi’an Daxing Hospital, Shaanxi, China
b International Doctoral School, University of Seville, Seville, Spain
c Ophthalmology Service, Hospital Hermanos Ameijeiras, La Habana, Cuba
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (5)
Show moreShow less
Tables (2)
Table 1. Summary of characteristics of the included articles.
Table 2. Summary estimates of diagnostic power and their 95% confidence intervals.
Show moreShow less
Additional material (1)
Abstract
Objectives

This meta-analysis has been conducted to evaluate the diagnostic accuracy of circulating microRNAs for the early diagnosis of prostate cancer (PCA).

Methods

A systematic literature search was performed (updated to February 18, 2021) in PubMed, EMBASE, Web of Science, Cochrane Library, Wanfang database and China National Knowledge Infrastructure (CNKI) to identify eligible studies. The pooled sensitivity (SEN), specificity (SPE), positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR), and area under curve (AUC) of the summary receiver-operating characteristic (SROC) curve were calculated for both overall and subgroup analysis. The meta-regression and subgroup analysis were performed to explore heterogeneity and Deeks’ funnel plot was used to assess publication bias.

Results

One hundred nineteen studies from 33 articles owned 8703 PCA patients and 4914 controls were included in our meta-analysis. The overall sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, diagnostic odds ratio and area under the curve were 0.79, 0.81, 4.1, 0.26, 16 and 0.87, respectively. The pooled sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, diagnostic odds ratio, and area under the curve of miR-21 in diagnosis of PCA were 0.86, 0.90, 8.3, 0.16, 52 and 0.94, respectively. Subgroup analysis suggested that the upregulated miRNA of serum type with large sample size could carry out a better diagnostic accuracy of PCA patients. Moreover, publication bias was not found.

Conclusions

Circulating microRNA, especially miR-21, can be used as a promising noninvasive biomarker in the early diagnosis of PCA.

Keywords:
Prostate cancer
microRNAs
Diagnosis
Meta-analysis
Resumen
Objetivos

Realizamos este meta-análisis para evaluar la precisión diagnóstica de los microARN (miARN) circulantes para el diagnóstico precoz del cáncer de próstata (CaP).

Métodos

Se realizó una búsqueda bibliográfica sistemática (actualizada al 18 de febrero de 2021) en PubMed, EMBASE, Web of Science, Cochrane Library, base de datos Wanfang y China National Knowledge Infrastructure (CNKI) para identificar estudios elegibles. La sensibilidad (SEN), especificidad (SPE), razón de verosimilitud positiva (PLR), razón de verosimilitud negativa (NLR), razón de probabilidades de diagnóstico (DOR) y el área bajo la curva (AUC) de la curva característica de funcionamiento del receptor (SROC) se agruparon tanto para el análisis general como para el de subgrupos. La meta-regresión y el análisis de subgrupos se realizaron para explorar la heterogeneidad y se utilizó el gráfico en embudo de Deek para evaluar el sesgo de publicación.

Resultados

Ciento diecinueve estudios de 33 artículos pertenecientes a 8.703 pacientes con CaP y 4.914 controles se incluyeron en nuestro meta-análisis. La sensibilidad, la especificidad, la razón de verosimilitud positiva, la razón de verosimilitud negativa, la odds ratio diagnóstica y el área bajo la curva para el análisis general fueron 0,79, 0,81, 4,1, 0,26, 16 y 0,87, respectivamente. La sensibilidad, especificidad, razón de verosimilitud positiva, razón de verosimilitud negativa, odds ratio diagnóstica y el área bajo la curva agrupadas de miR-21 en el diagnóstico de CaP fueron 0,86, 0,90, 8,3, 0,16, 52 y 0,94, respectivamente. El análisis de subgrupos sugirió que el miARN sérico regulado al alza con un tamaño de muestra grande podría llevar a cabo una mejor precisión diagnóstica de los pacientes con CaP. Además, no se encontró sesgo de publicación.

Conclusiones

El miARN circulante, especialmente el miR-21, puede utilizarse como un biomarcador no invasivo prometedor en el diagnóstico precoz del CaP.

Palabras clave:
Cáncer de próstata
microARN
Diagnóstico
Metaanálisis

Article

These are the options to access the full texts of the publication Actas Urológicas Españolas (English Edition)
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Actas Urológicas Españolas (English Edition)

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
Tools
Supplemental materials
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos